$BIOCQ
Biocept Inc

2015 Q4 Form 10-K Financial Statement

#000156459016014436 Filed on March 10, 2016

View on sec.gov

Income Statement

Concept 2015 Q4 2015 2014 Q4
Revenue $218.3K $609.9K $75.62K
YoY Change 188.65% 357.15% 302.24%
Cost Of Revenue $1.276M $4.596M $614.7K
YoY Change 107.53% 111.75% 7.84%
Gross Profit -$1.057M -$3.986M -$539.1K
YoY Change 96.16% 95.68% -2.26%
Gross Profit Margin -484.42% -653.58% -712.85%
Selling, General & Admin $2.669M $9.567M $2.122M
YoY Change 25.77% 30.36% 166.52%
% of Gross Profit
Research & Development $784.4K $2.858M $1.070M
YoY Change -26.71% -36.46% 50.56%
% of Gross Profit
Depreciation & Amortization $70.00K $261.0K $70.00K
YoY Change 0.0% 3.98% 0.0%
% of Gross Profit
Operating Expenses $3.453M $12.42M $3.192M
YoY Change 8.17% 4.97% 111.82%
Operating Profit -$4.510M -$16.41M -$3.731M
YoY Change 20.88% 18.29% 81.26%
Interest Expense -$150.0K $640.5K -$150.0K
YoY Change 0.0% -64.21% -76.19%
% of Operating Profit
Other Income/Expense, Net $40.00K -$537.1K $0.00
YoY Change -73.02% -100.0%
Pretax Income -$4.620M -$16.95M -$3.880M
YoY Change 19.07% 6.83% 57.09%
Income Tax $0.00 $1.608K $0.00
% Of Pretax Income
Net Earnings -$4.618M -$16.95M -$3.882M
YoY Change 18.96% 6.83% 57.02%
Net Earnings / Revenue -2115.37% -2779.03% -5132.89%
Basic Earnings Per Share -$0.73 -$3.07 -$0.87
Diluted Earnings Per Share -$0.73 -$3.07 -$0.87
COMMON SHARES
Basic Shares Outstanding 6.307M 5.513M 4.450M
Diluted Shares Outstanding 6.307M 5.513M 4.450M

Balance Sheet

Concept 2015 Q4 2015 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.820M $8.820M $5.360M
YoY Change 64.55% 64.55% 7557.14%
Cash & Equivalents $8.820M $8.820M $5.365M
Short-Term Investments
Other Short-Term Assets $440.0K $440.0K $340.0K
YoY Change 29.41% 29.41% -57.5%
Inventory $350.0K $350.0K $188.7K
Prepaid Expenses
Receivables $30.00K $30.00K $10.60K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $9.640M $9.640M $5.903M
YoY Change 63.32% 63.39% 508.31%
LONG-TERM ASSETS
Property, Plant & Equipment $950.0K $950.0K $662.4K
YoY Change 43.41% 43.94% 84.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $23.19K
YoY Change 4538.8%
Total Long-Term Assets $946.9K $950.0K $662.4K
YoY Change 42.95% 41.79% 84.32%
TOTAL ASSETS
Total Short-Term Assets $9.640M $9.640M $5.903M
Total Long-Term Assets $946.9K $950.0K $662.4K
Total Assets $10.59M $10.59M $6.565M
YoY Change 61.26% 61.19% 393.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $632.5K $630.0K $641.4K
YoY Change -1.38% -1.56% -58.37%
Accrued Expenses $966.9K $970.0K $699.9K
YoY Change 38.15% 38.57% -68.78%
Deferred Revenue
YoY Change
Short-Term Debt $40.00K $40.00K $30.00K
YoY Change 33.33% 33.33% -99.59%
Long-Term Debt Due $1.700M $1.700M $60.00K
YoY Change 2733.33% 2733.33%
Total Short-Term Liabilities $3.341M $3.340M $1.431M
YoY Change 133.49% 133.57% -89.26%
LONG-TERM LIABILITIES
Long-Term Debt $2.930M $2.930M $4.800M
YoY Change -38.96% -38.96%
Other Long-Term Liabilities $620.0K $620.0K $550.0K
YoY Change 12.73% 12.73% 19.57%
Total Long-Term Liabilities $3.553M $3.550M $5.355M
YoY Change -33.64% -33.64% 1059.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.341M $3.340M $1.431M
Total Long-Term Liabilities $3.553M $3.550M $5.355M
Total Liabilities $6.894M $6.890M $6.786M
YoY Change 1.6% 1.47% -50.78%
SHAREHOLDERS EQUITY
Retained Earnings -$155.2M -$138.3M
YoY Change 12.26% 12.96%
Common Stock $158.9M $138.1M
YoY Change 15.11% 726665442.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.693M $3.690M -$220.6K
YoY Change
Total Liabilities & Shareholders Equity $10.59M $10.59M $6.565M
YoY Change 61.26% 61.19% 393.72%

Cashflow Statement

Concept 2015 Q4 2015 2014 Q4
OPERATING ACTIVITIES
Net Income -$4.618M -$16.95M -$3.882M
YoY Change 18.96% 6.83% 57.02%
Depreciation, Depletion And Amortization $70.00K $261.0K $70.00K
YoY Change 0.0% 3.98% 0.0%
Cash From Operating Activities -$4.250M -$15.15M -$3.190M
YoY Change 33.23% 3.91% 141.67%
INVESTING ACTIVITIES
Capital Expenditures -$50.00K $165.2K -$190.0K
YoY Change -73.68% -58.18%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$50.00K -$170.0K -$190.0K
YoY Change -73.68% -56.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.788M
YoY Change -43.72%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 590.0K 18.78M -70.00K
YoY Change -942.86% -7.35% -106.42%
NET CHANGE
Cash From Operating Activities -4.250M -15.15M -3.190M
Cash From Investing Activities -50.00K -170.0K -190.0K
Cash From Financing Activities 590.0K 18.78M -70.00K
Net Change In Cash -3.710M 3.460M -3.450M
YoY Change 7.54% -34.72% 1400.0%
FREE CASH FLOW
Cash From Operating Activities -$4.250M -$15.15M -$3.190M
Capital Expenditures -$50.00K $165.2K -$190.0K
Free Cash Flow -$4.200M -$15.32M -$3.000M
YoY Change 40.0% 2.27% 127.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-537115
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16947918
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-15866046
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
445
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
138066008
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-220569
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3340788
CY2014Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
4731322
CY2015Q4 bioc Interest Payable Noncurrent
InterestPayableNoncurrent
153547
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
470172
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19670054
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4449603
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19670054
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4449603
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5686398
CY2015 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3880386
CY2014 us-gaap Costs And Expenses
CostsAndExpenses
14007339
CY2015 us-gaap Costs And Expenses
CostsAndExpenses
17020712
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-13873924
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-16410803
CY2014 us-gaap Interest Expense
InterestExpense
1789680
CY2015 us-gaap Interest Expense
InterestExpense
640478
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
200936
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-931
CY2015 us-gaap Other Income
OtherIncome
102432
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1506
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1608
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-16949526
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1822661
CY2014 bioc Stock Issued During Period Value For Conversion Of Convertible Shareholder Notes Payable
StockIssuedDuringPeriodValueForConversionOfConvertibleShareholderNotesPayable
7111999
CY2014 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2475620
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16458104
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4497790
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5201997
CY2014 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2137004
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-138287022
CY2015Q4 us-gaap Assets
Assets
10586918
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
699903
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
632538
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
641406
CY2014Q4 us-gaap Assets
Assets
6565053
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
966899
CY2015Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
2638487
CY2015Q4 bioc Supplier Financings
SupplierFinancings
42369
CY2014Q4 bioc Interest Payable Noncurrent
InterestPayableNoncurrent
54537
CY2014Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
55800
CY2015Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
291189
CY2014Q4 bioc Supplier Financings
SupplierFinancings
33674
CY2015Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1588058
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2857770
CY2014 us-gaap Cost Of Revenue
CostOfRevenue
2170548
CY2014 us-gaap Revenues
Revenues
133415
CY2015 us-gaap Cost Of Revenue
CostOfRevenue
4596158
CY2014Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
68801
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
1967
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
158927316
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-155236548
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
3692735
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10586918
CY2014Q4 us-gaap Liabilities
Liabilities
6785622
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
500179
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16538963
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16538963
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1990616
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15864540
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3997797
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3997797
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.97
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.97
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-12456014
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
394925
CY2015 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9760060
CY2014 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
192511
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6565053
CY2015 us-gaap Revenues
Revenues
609909
CY2014 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
19546
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
64300
CY2015Q4 us-gaap Liabilities
Liabilities
6894183
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014 bioc Adjustments To Additional Paid In Capital Warrant Issued In Connection With Credit Facility
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithCreditFacility
233107
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1377824
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.71
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8766946
CY2015 bioc Stock Issued During Period Value Pursuant To Stock Purchase Agreement
StockIssuedDuringPeriodValuePursuantToStockPurchaseAgreement
958000
CY2015 bioc Exercise Of Common Stock Warrants Value
ExerciseOfCommonStockWarrantsValue
9760060
CY2014 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
6600000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
251203
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
261409
CY2014 bioc Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
13779
CY2015 bioc Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
34437
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
1822661
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
1377824
CY2014 us-gaap Paid In Kind Interest
PaidInKindInterest
1445068
CY2015 us-gaap Paid In Kind Interest
PaidInKindInterest
120663
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1400
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
23600
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
82126
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
126106
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
401355
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
80432
CY2014 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-500
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-981869
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-51790
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1046559
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
240901
CY2014 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
58936
CY2015 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
110021
CY2014 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
38178
CY2015 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
1163
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14575652
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-15154841
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
165160
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-394925
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-165160
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
17390240
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9788057
CY2014 bioc Proceeds From Payments For Equipment Financings
ProceedsFromPaymentsForEquipmentFinancings
-23250
CY2015 bioc Proceeds From Payments For Equipment Financings
ProceedsFromPaymentsForEquipmentFinancings
-74697
CY2015 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
71232
CY2014 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2346000
CY2015 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
625440
CY2014 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
365000
CY2014 bioc Proceeds From Issuance Of Convertible Notes And Warrants
ProceedsFromIssuanceOfConvertibleNotesAndWarrants
175000
CY2014 bioc Net Proceeds From Borrowings On Credit Facility And Warrants
NetProceedsFromBorrowingsOnCreditFacilityAndWarrants
4897502
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
20265981
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
18776748
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5295404
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3456747
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69178
CY2014 us-gaap Interest Paid Net
InterestPaidNet
402075
CY2015 us-gaap Interest Paid Net
InterestPaidNet
405715
CY2014 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
800
CY2015 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2184
CY2014 bioc Financial Guarantee Insurance Contracts Premium Payable
FinancialGuaranteeInsuranceContractsPremiumPayable
62774
CY2015 bioc Financial Guarantee Insurance Contracts Premium Payable
FinancialGuaranteeInsuranceContractsPremiumPayable
79896
CY2014 us-gaap Other Noncash Income
OtherNoncashIncome
44559
CY2014 us-gaap Financial Guarantee Insurance Contracts Premium Receivable Premium Payments Received
FinancialGuaranteeInsuranceContractsPremiumReceivablePremiumPaymentsReceived
10955
CY2014 bioc Fair Value Of Common Stock Warrant Issued
FairValueOfCommonStockWarrantIssued
135222
CY2014Q1 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
69421047
CY2014Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1652851
CY2014Q1 bioc Underwriter Common Stock Grants Period
UnderwriterCommonStockGrantsPeriod
P45D
CY2014Q1 bioc Shares Issued To Underwriters Under Over Allotment Options
SharesIssuedToUnderwritersUnderOverAllotmentOptions
285000
CY2014Q1 bioc Shares Issued To Underwriters Under Over Allotment Options Per Share
SharesIssuedToUnderwritersUnderOverAllotmentOptionsPerShare
9.30
CY2014Q1 bioc Class Of Warrant Or Right Expiry Period
ClassOfWarrantOrRightExpiryPeriod
P5Y
CY2014Q1 bioc Underwriting Initial Public Offering Issuance Costs
UnderwritingInitialPublicOfferingIssuanceCosts
279760
CY2014Q1 bioc Underwriting Discounts From Issuance Initial Public Offering
UnderwritingDiscountsFromIssuanceInitialPublicOffering
1330000
CY2014Q1 bioc Deferred Offering Costs Classified To Additional Paid In Capital
DeferredOfferingCostsClassifiedToAdditionalPaidInCapital
932136
CY2015Q4 bioc Fixed Assets Purchased Under Capital Lease Obligations
FixedAssetsPurchasedUnderCapitalLeaseObligations
337085
CY2014Q4 us-gaap Deferred Costs
DeferredCosts
63111
CY2015Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.56
CY2015 bioc Class Of Warrant Or Right Expiry Period
ClassOfWarrantOrRightExpiryPeriod
P5Y
CY2015 bioc Shares Issued To Underwriters Under Over Allotment Options Grant Date Fair Value
SharesIssuedToUnderwritersUnderOverAllotmentOptionsGrantDateFairValue
7690395
CY2015 bioc Underwriter Common Stock Grants Period
UnderwriterCommonStockGrantsPeriod
P45D
CY2015 bioc Common Shares Issuable To Underwriters Under Granted Option
CommonSharesIssuableToUnderwritersUnderGrantedOption
1200000
CY2015Q4 bioc Shares Issued To Underwriters Under Over Allotment Options Per Share
SharesIssuedToUnderwritersUnderOverAllotmentOptionsPerShare
1.25
CY2015 bioc Common Shares Issuable To Underwriters Under Warrants Granted
CommonSharesIssuableToUnderwritersUnderWarrantsGranted
1200000
CY2015 bioc Warrants Issued Grant Date Fair Value
WarrantsIssuedGrantDateFairValue
1627396
CY2015 bioc Offering Costs Recorded In Prepaid Expenses And Other Current Assets Reclassified To Common Stock Issuance Costs
OfferingCostsRecordedInPrepaidExpensesAndOtherCurrentAssetsReclassifiedToCommonStockIssuanceCosts
63111
CY2014Q4 bioc Fixed Assets Purchased Under Capital Lease Obligations
FixedAssetsPurchasedUnderCapitalLeaseObligations
140267
CY2015 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. The Company and Business Activities </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biocept, Inc., or the Company, was founded in California in May 1997 and is a commercial-stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company&#8217;s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July&#160;23, 2013. </p></div>
CY2014Q1 us-gaap Cost Of Revenue
CostOfRevenue
658315
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1008929
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1876912
CY2014Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11142
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3527023
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-5127871
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2014Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4449603
CY2014Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4449603
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates these estimates and judgments, including those related to inventories, long-lived assets, convertible debt, derivative liabilities, income taxes, and stock-based compensation. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. </p></div>
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. The Company has not experienced losses in such accounts. Management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2013, the Company entered into a research support agreement with a not-for-profit tax-exempt organization, Dana-Farber Partners Cancer Care, Inc., or Dana-Farber. For the year ended December&#160;31, 2014, 32% of the revenues earned were billed through this relationship. In addition, 72% of the receivables were due from Dana-Farber at December&#160;31, 2014. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2014, the Company entered into a research support agreement with a not-for-profit tax-exempt organization, The University of Texas MD Anderson Cancer Center, or MD Anderson. For the years ended December&#160;31, 2014 and 2015, 2% and 5%, respectively, of the revenues earned were billed through this relationship. In addition, 28% and 86% of the receivables were due from MD Anderson at December&#160;31, 2014 and 2015, respectively. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of credit risk with respect to revenues and accounts receivable are primarily limited to certain clients including Dana-Farber and MD Anderson, and geographies to which the Company provides a significant volume of its services, and to specific payors of our services such as Medicare and individual insurance companies. Approximately 48% of commercial accessions billed from January 1, 2015 through December 31, 2015 were subject to Medicare reimbursement, and approximately 47% and 42% of commercial revenues and total revenues, respectively, during the twelve months ended December 31, 2015 were associated with Medicare.&nbsp;&nbsp;The Company&#8217;s client base consists of a large number of geographically dispersed clients diversified across various customer types. For the year ended December&#160;31, 2014, revenues derived from clients within the states of Texas, Massachusetts, and California accounted for approximately 34%, 32% and 15%, respectively, of total revenues. For the year ended December&#160;31, 2015, revenues derived from clients within the states of Texas, California and Maryland accounted for approximately 32%, 18%, and 12%, respectively, of total revenues. For the year ended December&#160;31, 2014, the first, second, and third most significant clients accounted for approximately 32%, 20%, and 6%, respectively, of total revenues. For the year ended December&#160;31, 2015, the first, second, and third most significant clients accounted for approximately 12%, 9%, and 5%, respectively, of total revenues.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one reportable business segment and historically has derived revenues only from the United States, with international revenues of $16,027, or approximately 3% of our net revenues, commencing in 2015 and received through the twelve months ended December 31 of such year.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain components used in the Company&#8217;s current or planned products are available from only one supplier, and substitutes for these components cannot be obtained easily or would require substantial design or manufacturing modifications or identification and qualification of alternative sources. </p></div>
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
1600000
CY2015Q1 bioc Proceeds From Issuance Of Follow On Public Offering
ProceedsFromIssuanceOfFollowOnPublicOffering
9100000
CY2015Q1 bioc Non Underwriter Deferred Offering Costs
NonUnderwriterDeferredOfferingCosts
300000
CY2015 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2015 us-gaap Concentration Risk Supplier
ConcentrationRiskSupplier
one supplier
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2014 us-gaap Depreciation
Depreciation
251000
CY2015 us-gaap Depreciation
Depreciation
261000
CY2014Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1587
CY2014Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2014 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2015 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2014 us-gaap Prior Period Reclassification Adjustment
PriorPeriodReclassificationAdjustment
23194
CY2015Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
12778
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1900000
CY2014Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.00
CY2014Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
17400000
CY2014Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
900000
CY2015 bioc Class Of Warrant Or Rights Term
ClassOfWarrantOrRightsTerm
P5Y
CY2014Q1 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
69421047
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1652851
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
73151
CY2014Q1 bioc Common Stock Capital Shares Reserved For Future Issuance Lockup Period
CommonStockCapitalSharesReservedForFutureIssuanceLockupPeriod
P180D
CY2014Q1 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
2500000
CY2014Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1000000
CY2014Q1 bioc Stock Issuance Costs Current
StockIssuanceCostsCurrent
900000
CY2014Q1 bioc Initial Public Offering Discount
InitialPublicOfferingDiscount
1300000
CY2014Q1 us-gaap Interest Paid
InterestPaid
27043
CY2014 us-gaap Payments To Suppliers
PaymentsToSuppliers
70000
CY2015Q1 bioc Shares Issued To Underwriters Under Over Allotment Options Grant Date Fair Value
SharesIssuedToUnderwritersUnderOverAllotmentOptionsGrantDateFairValue
7690395
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
177500
CY2015Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.56
CY2015Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
9100000
CY2015Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8800000
CY2015Q1 bioc Underwriter Common Stock Grants Period
UnderwriterCommonStockGrantsPeriod
P45D
CY2015Q1 bioc Shares Issued To Underwriters Under Over Allotment Options
SharesIssuedToUnderwritersUnderOverAllotmentOptions
1200000
CY2015Q1 bioc Shares Issued To Underwriters Under Over Allotment Options Per Share
SharesIssuedToUnderwritersUnderOverAllotmentOptionsPerShare
1.25
CY2015Q1 bioc Issuance Of Warrants To Purchase Common Stock Shares
IssuanceOfWarrantsToPurchaseCommonStockShares
1200000
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q1 bioc Warrants Issued Grant Date Fair Value
WarrantsIssuedGrantDateFairValue
1627396
CY2015 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
200000
CY2015 bioc Underwriting Discounts
UnderwritingDiscounts
700000
CY2015Q4 bioc Non Underwriter Deferred Offering Costs
NonUnderwriterDeferredOfferingCosts
300000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
165000
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
10.00
CY2015Q4 bioc Warrant Preferred Shares Outstanding
WarrantPreferredSharesOutstanding
1587
CY2014Q4 bioc Shares Issued To Underwriters Under Over Allotment Options
SharesIssuedToUnderwritersUnderOverAllotmentOptions
285000
CY2015Q1 bioc Underwriter Common Stock Grants Period
UnderwriterCommonStockGrantsPeriod
P45D
CY2014Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2922303
CY2015Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
2518158
CY2014Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
209844
CY2015Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
143726
CY2014Q4 bioc Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
681508
CY2015Q4 bioc Computer Equipment And Software Gross
ComputerEquipmentAndSoftwareGross
577898
CY2014Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
506328
CY2015Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
514614
CY2014Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
878447
CY2015Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
914179
CY2014Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
72172
CY2015Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
70815
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5270602
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4739390
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4608180
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3793210
CY2014Q4 us-gaap Interest Payable Current
InterestPayableCurrent
33125
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
28981
CY2014Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
82241
CY2015Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
128753
CY2014Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
276574
CY2015Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
307845
CY2014Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
302763
CY2015Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
376100
CY2015Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
76574
CY2014Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1070
CY2015Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
139
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
31170
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4130
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
17337
CY2015 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
1076000
CY2015 bioc Related Party Transaction Number Of Related Parties
RelatedPartyTransactionNumberOfRelatedParties
5
CY2014Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2346000
CY2014Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
513603
CY2012 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
536000
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
53000000
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q1 bioc Number Of Preferred Stock Share Previously Authorized
NumberOfPreferredStockSharePreviouslyAuthorized
100000000
CY2014 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.08
CY2014 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
0
CY2015 us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
The holders of preferred shares had the right to one vote for each common share into which the preferred shares were convertible.
CY2014 bioc Proceeds From Issuance Of Common Stock Threshold For Automatic Conversion Of Preferred Stock
ProceedsFromIssuanceOfCommonStockThresholdForAutomaticConversionOfPreferredStock
20000000
CY2014Q4 bioc Issuance Per Share Of Common Stock Threshold For Automatic Conversion Of Preferred Stock
IssuancePerShareOfCommonStockThresholdForAutomaticConversionOfPreferredStock
25.20
CY2015 us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
The convertible preferred shares could have been converted into common shares at any time at the option of the holder utilizing the then effective Series A preferred conversion price. All preferred shares would have been automatically converted into common shares utilizing the then effective Series A preferred conversion price upon a) the election of the holders of a majority of the outstanding shares of Series A preferred stock, or b) the closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the sale of the Company’s common stock if gross proceeds are at least $20,000,000 and the per share price is at least $25.20.
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
333106
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
647298
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
74210
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
906194
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1323926
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
88979
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2141141
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1940701
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.14
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.71
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.77
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.29
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.00
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.61
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.16
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M6D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
325931
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
479652
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2703000
CY2015Q4 bioc Common Stock Warrants Exercisable Intrinsic Value
CommonStockWarrantsExercisableIntrinsicValue
0
CY2015Q4 bioc Common Stock Warrants Outstanding Intrinsic Value
CommonStockWarrantsOutstandingIntrinsicValue
0
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1768586
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4572731
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1506
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1608
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1506
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1608
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5393944
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5762293
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-813039
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-334494
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
14374
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
6331451
CY2014 bioc Additional Cash Compensation Expense
AdditionalCashCompensationExpense
150000
CY2014Q1 bioc Annual Cash Compensation Expense
AnnualCashCompensationExpense
225000
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10417277
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12460565
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8819872
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
34852
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
159128
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
334609
CY2014 bioc Income Tax Reconciliation Nondeductible Expense Interest
IncomeTaxReconciliationNondeductibleExpenseInterest
399249
CY2015 bioc Income Tax Reconciliation Nondeductible Expense Interest
IncomeTaxReconciliationNondeductibleExpenseInterest
-316
CY2014 bioc Income Tax Reconciliation Expiration Of Net Operating Losses
IncomeTaxReconciliationExpirationOfNetOperatingLosses
1136317
CY2015 bioc Income Tax Reconciliation Expiration Of Net Operating Losses
IncomeTaxReconciliationExpirationOfNetOperatingLosses
796699
CY2014 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
127491
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
164967
CY2014 us-gaap Income Tax Reconciliation Tax Contingencies State And Local
IncomeTaxReconciliationTaxContingenciesStateAndLocal
302647
CY2015 us-gaap Income Tax Reconciliation Tax Contingencies State And Local
IncomeTaxReconciliationTaxContingenciesStateAndLocal
746238
CY2015 bioc Income Tax Reconciliation Section Three Eight Two Limitation
IncomeTaxReconciliationSectionThreeEightTwoLimitation
48484354
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
36989
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-1041
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4287276
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-44132033
CY2014 bioc Percent Of Uncertain Income Tax Positions Recognized
PercentOfUncertainIncomeTaxPositionsRecognized
0.50
CY2015 bioc Percent Of Uncertain Income Tax Positions Recognized
PercentOfUncertainIncomeTaxPositionsRecognized
0.50
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
47329815
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6204024
CY2014Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
5242144
CY2015Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2235914
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1216600
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1234413
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
198945
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
181134
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
53987504
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
9855485
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
53987504
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9855485
CY2015Q4 bioc Percentage Of Change In Ownership
PercentageOfChangeInOwnership
0.50
CY2015 bioc Period Of Change In Ownership
PeriodOfChangeInOwnership
P3Y
CY2015 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-07-31
bioc Lease Payments Waived By Landlord
LeasePaymentsWaivedByLandlord
503000
bioc Forfeited Of Long Term Deposit
ForfeitedOfLongTermDeposit
269000
CY2014Q1 bioc Exercisable Period Of Warrants
ExercisablePeriodOfWarrants
P5Y
CY2013Q3 bioc Warrant Coverage Amount
WarrantCoverageAmount
502605
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
50260
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1308987
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1348257
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1388705
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1430366
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
855136
CY2014Q1 us-gaap Assets
Assets
11289508
CY2014Q2 us-gaap Assets
Assets
13332475
CY2014Q3 us-gaap Assets
Assets
9849674
CY2014Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
473080
CY2014Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5176235
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2904013
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3711629
CY2014Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3731259
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-2996840
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-3859794
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-3881541
CY2014Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5314253
CY2014Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5354839
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
9356778
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
6855762
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
3319532
CY2014Q1 us-gaap Revenues
Revenues
28275
CY2014Q2 us-gaap Revenues
Revenues
19245
CY2014Q3 us-gaap Revenues
Revenues
10274
CY2014Q4 us-gaap Revenues
Revenues
75621
CY2014Q2 us-gaap Cost Of Revenue
CostOfRevenue
359364
CY2014Q3 us-gaap Cost Of Revenue
CostOfRevenue
538181
CY2014Q4 us-gaap Cost Of Revenue
CostOfRevenue
614688
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1107678
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1310905
CY2014Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1070278
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1032855
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1060812
CY2014Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1231418
CY2014Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
423361
CY2014Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
812005
CY2014Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
890496
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.96
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.96
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2617275
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4449603
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4449603
CY2014Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2617275
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4449603
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4449603
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19294706
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16523975
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12541919
CY2015Q1 us-gaap Assets
Assets
20899513
CY2015Q2 us-gaap Assets
Assets
18317659
CY2015Q3 us-gaap Assets
Assets
14196386
CY2015Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5083216
CY2015Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4234552
CY2015Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3877362
CY2015Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3553395
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
13582795
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
11049961
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
6928277
CY2015Q1 us-gaap Revenues
Revenues
150002
CY2015Q2 us-gaap Revenues
Revenues
76768
CY2015Q3 us-gaap Revenues
Revenues
164856
CY2015Q4 us-gaap Revenues
Revenues
218283
CY2015Q1 us-gaap Cost Of Revenue
CostOfRevenue
1147682
CY2015Q2 us-gaap Cost Of Revenue
CostOfRevenue
1013075
CY2015Q3 us-gaap Cost Of Revenue
CostOfRevenue
1159710
CY2015Q4 us-gaap Cost Of Revenue
CostOfRevenue
1275691
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
651420
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
744242
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
677729
CY2015Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
784379
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1292049
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1359226
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1630608
CY2015Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1404515
CY2015Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
709456
CY2015Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
851109
CY2015Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1055653
CY2015Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1264168
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3650605
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3890884
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4358844
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4510470
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-3800728
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-4035105
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-4496193
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-4617500
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2015Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2015Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10372667
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17998969
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18727806
CY2015Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18921945
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10372667
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17998969
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18727806
CY2015Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18921945
CY2015Q1 bioc Reclassification Of Revenue Generation Cost From Research And Development To Cost Of Revenue
ReclassificationOfRevenueGenerationCostFromResearchAndDevelopmentToCostOfRevenue
290709
CY2015Q2 bioc Reclassification Of Revenue Generation Cost From Research And Development To Cost Of Revenue
ReclassificationOfRevenueGenerationCostFromResearchAndDevelopmentToCostOfRevenue
27856

Files In Submission

Name View Source Status
0001564590-16-014436-index-headers.html Edgar Link pending
0001564590-16-014436-index.html Edgar Link pending
0001564590-16-014436.txt Edgar Link pending
0001564590-16-014436-xbrl.zip Edgar Link pending
bioc-10k_20151231.htm Edgar Link pending
bioc-20151231.xml Edgar Link completed
bioc-20151231.xsd Edgar Link pending
bioc-20151231_cal.xml Edgar Link unprocessable
bioc-20151231_def.xml Edgar Link unprocessable
bioc-20151231_lab.xml Edgar Link unprocessable
bioc-20151231_pre.xml Edgar Link unprocessable
bioc-ex311_10.htm Edgar Link pending
bioc-ex312_9.htm Edgar Link pending
bioc-ex321_8.htm Edgar Link pending
bioc-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending